PSEN1 and Alzheimer disease: Altogether, our data show that a chronic oral treatment with anatabine reduces β-amyloidosis and neuroinflammation and alleviates some behavioral impairments in Tg PS1/APPswe supporting further exploration of anatabine as a possible disease modifying agent for the treatment of AD.